In this webinar, genomics experts Drs. Mark Kiel and Alex Joyner describe the deep and invaluable connection between therapeutics development and genomics, and how to obtain and use NGS data to improve outcomes.

Pursue 18 C ( Uploaded): Hematology – Malignant Lymphoid & Plasmacytic Diseases

“Chronic Lymphocytic Leukemia”
Classification , Morphology, Flow, Molecular, Prognostic, Risk Classification.


Lecture conducted by:
Dr Ruchi Gupta,
MD, (PGIMER, Chandigarh)
Additional Professor (Lab Hematology)
Department of Hematology
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow.
Areas of Interest : Malignant Hematology - MDS, AML, MM
Benign Hematology – Thalassemia and Bleeding disorders
Multiple publications in National & International Journals.

HEY GUYS THIS IS THE LAST PART OF THE PAPER ON HAEM5 DISCUSSION OF THE CHANHES FROM HAEM 4R IN SPECIFIC ...FROM THE NEXT LECTURE WE WILL DELVE INTO EACH TOPIC IN DETAIL

Madeleine Lehander, Ph.D. Student, Woll and Jacobsen Groups, Karolinska Institute - Department of Medicine, Huddinge, Sweden leads a discussion on T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes.

"CLL – diagnosis, management, treatment and outcome in the new era with kinase inhibitors"
Dr Francesco Forconi MD, DM, PhD, FRCPath Associate Professor in Haematological Oncology, Honorary Consultant in Haematology stresses the importance of Patients in helping the research team at Southampton to development improvements to treatments and to the quality of life for patients.

His talk starts with an overview: Diagnosis of CLL. why so many are on watch and wait, What is CLL? How CLL is diagnosed. How diagnostic tools have improved and the identification of prognostic and predictive characteristics became possible. How the origin of a CLL and the characteristics of the immunoglobulin genes are significant as prognostic and predictive information that aid in understanding potential different clinical courses.

Dr Forconi goes on to explain the significance of immunoglobulin expression on the surface of a CLL cell, among other tests.

Fitness of a patient has historically determined the treatment that a patient can tolerate . The new treatments like ibrutinib and venetoclax are now in use by patients unable to tolerate, who fail or are unsuitable for treatment of toxic therapies These are proving to further improve survival. Patients are now providing data that can potentially further improve how CLL is treated into the future. The ongoing research into this data and use of these drugs by many at Southampton and around the globe will continue to generate improvements into the quality of life and survival of patients with CLL.


.